Boston Scientific Corporation announced unaudited sales results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported sales of approximately $2.41 billion during the fourth quarter ended December 31, 2017. This represents growth of approximately 9.9% on a reported basis, approximately 8.1% on an operational basis (excludes the impact of changes in foreign currency exchange rates) and approximately 6.8% on an organic basis, all compared to the prior year period. For the year, the company reported sales of approximately $9.05 billion. This represents growth of approximately 7.9% on a reported basis, approximately 7.8% on an operational basis and approximately 6.6% on an organic basis, all compared to the prior year period.